Jaka jest cena za Myovant Sciences Ltd. (MYOV)

Cena za Myovant Sciences Ltd. (MYOV) wynosi $26.98

Jaka jest kapitalizacja rynkowa dla Myovant Sciences Ltd. (MYOV)

Kapitalizacja rynkowa dla Myovant Sciences Ltd. (MYOV) wynosi $2.62B

Myovant Sciences Ltd. (MYOV) Historia Cen

Myovant Sciences Ltd. is a biopharmaceutical company focused on innovating healthcare solutions for both women and men. Its flagship product is relugolix, an orally administered, once-daily small molecule that functions as a gonadotropin-releasing hormone (GnRH) receptor antagonist. This medication is indicated for conditions such as heavy menstrual bleeding caused by uterine fibroids, pain associated with endometriosis, and advanced prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin agonist, currently in Phase II clinical trials for treating female infertility within assisted reproductive procedures. Myovant collaborates with Pfizer Inc. for the development and commercialization of relugolix across oncology and women's health sectors. Incorporated in 2016, initially as Roivant Endocrinology Ltd. before rebranding to Myovant Sciences Ltd. in May of that year, the firm is based in London, United Kingdom, and operates as a subsidiary of Sumitovant Biopharma Ltd.

Rok	Wydajność
2023	0.28%
2022	73.07%
2021	-37.07%
2020	50.47%
2019	-4.83%
2018	41.15%
2017	8.58%
2016	0.00%

Rok

Wydajność

2023

0.28%

2022

73.07%

2021

-37.07%

2020

50.47%

2019

-4.83%

2018

41.15%

2017

8.58%

2016

0.00%

Firma	Cena akcji	Zmiana 1r%	Kraj
Vertex Pharmaceuticals Incorporated VRTX.US	$549.38	41.20%	US
Argenx SE ARGX.US	$1.05K	47.75%	NL
Moderna, Inc. MRNA.US	$148.35	491.02%	US
CSL Limited CSL.AX	$122.63	-12.65%	AU
Lonza Group AG LONN.SW	$762.91	6.87%	CH

Firma

Cena akcji

Zmiana 1r%

Kraj